0.5301
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors - MyChesCo
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now - MSN
Verrica Pharmaceuticals appoints new board member By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals expands board with new director By Investing.com - Investing.com Canada
Verrica Pharmaceuticals appoints new board member - Investing.com India
Verrica Pharmaceuticals expands board with new director - Investing.com India
Verrica Pharmaceuticals Appoints Dr. Corcoran as Director - TipRanks
Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors - The Manila Times
Strategic Move: Verrica Adds Formation Bio CDO to Board Amid YCANTH Success - Stock Titan
Verrica Pharmaceuticals to Present at Needham Healthcare Conference - MSN
Harmony, Lungpacer, Verrica and Arbutus make C-suite hires - The Business Journals
Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive: Verrica Pharmaceuticals CEO Fireside Chat at Major Healthcare Conference - Stock Titan
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Verrica Pharmaceuticals appoints new CMO to advance skin treatments By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer - GlobeNewswire
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
Verrica Pharmaceuticals appoints new CMO to advance skin treatments - Investing.com
Dermatology Drug Pioneer Joins Verrica to Accelerate YCANTH Growth - Stock Titan
Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News
Verrica Pharmaceuticals Reports Positive Q4 2024 Results - TipRanks
Verrica Pharmaceuticals’ chief legal officer sells shares for $2,804 By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals’ chief legal officer sells shares for $2,804 - Investing.com
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates - MSN
Equities Analysts Offer Predictions for VRCA Q4 Earnings - Defense World
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MSN
Verrica Pharmaceuticals (NASDAQ:VRCA) Earns “Hold” Rating from Needham & Company LLC - Defense World
Brookline Capital Management Comments on VRCA Q1 Earnings - Defense World
GLP-1 Receptor Agonist Market Projected To Witness Substantial Growth, 2025-2032: Verrica Pharmaceuticals, - EIN News
Verrica Pharmaceuticals stock hits 52-week low at $0.57 By Investing.com - Investing.com Australia
Verrica Pharmaceuticals stock hits 52-week low at $0.57 - Investing.com India
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 - Investing.com Australia
Strategic Growth and Market Positioning Drive Buy Rating for Verrica Pharmaceuticals - TipRanks
Verrica Pharma's Q4 Net Loss Narrows, Revenue Declines - Nasdaq
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... - Yahoo
Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlig - GuruFocus.com
Verrica Pharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Verrica Pharmaceuticals beats EPS, misses revenue in Q4 2024 By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Verrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c) - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):